COMMUNIQUÉS West-GlobeNewswire

Cancer Genetics Appoints Renowned Biotech Entrepreneur Dr. Thomas F. Widmann to its Board of Directors

27/11/2017 - 14:00

RUTHERFORD, N.J., Nov. 27, 2017 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq: CGIX ), a leader in enabling precision medicine for oncology through molecular markers and diagnostics, today announced the appointment [...]

Intra-Cellular Therapies to Participate at the 29th Annual Piper Jaffray Healthcare Conference

27/11/2017 - 14:00

NEW YORK, Nov. 27, 2017 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI ), a biopharmaceutical company focused on the development of therapeutics for central nervous system ("CNS") disorders, today [...]

Medovex Corporation Submits IDE with the Food and Drug Administration for its DenerveX System

27/11/2017 - 14:00

ATLANTA, Nov. 27, 2017 (GLOBE NEWSWIRE) -- Medovex Corporation (NASDAQ: MDVX ) ("Medovex" or the "Company"), the developer of the DenerveX® System, a new and novel device designed for enduring relief of Facet Joint [...]

aTyr Pharma Doses First Subjects in Phase 1 Trial of iMod.Fc (ATYR1923)

27/11/2017 - 14:00

– Second Physiocrine-based therapeutic candidate enters the clinic – – Top-line data expected in 2Q 2018 – – iMod.Fc (ATYR1923) to target interstitial lung diseases with an immune component – SAN DIEGO, Nov. 27, 2017 ( [...]

Novo Nordisk A/S - Share repurchase programme

27/11/2017 - 13:50

Bagsværd, Denmark, 27 November 2017 - On 1 November 2017, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No. 596/2014 of the European Parliament and Council of 16 April [...]

Avadel Pharmaceuticals to Present at the 29th Annual Piper Jaffray Healthcare Conference

27/11/2017 - 13:30

DUBLIN, Ireland, Nov. 27, 2017 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (NASDAQ: AVDL ), today announced that Mike Kanan, Chief Financial Officer, and Lauren Stival, Senior Director, Investor Relations, will [...]

TG Therapeutics Announces Initiation of National Cancer Institute/SWOG-Sponsored Randomized Phase II Trial in Follicular Lymphoma

27/11/2017 - 13:30

NEW YORK, Nov. 27, 2017 (GLOBE NEWSWIRE) -- TG Therapeutics (NASDAQ: TGTX ) announced today that along with SWOG, the global cancer clinical trials group funded by the National Cancer Institute (NCI), it has initiated a [...]

Forward Pharma to Participate in Investor Conferences in December

27/11/2017 - 13:30

COPENHAGEN, Denmark, Nov. 27, 2017 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ: FWP ) (the “Company”) today announced that Dr. Claus Bo Svendsen, the Company’s Chief Executive Officer, will participate in two [...]

The Joint Corp. to Present at the 6th Annual Roth Utah Active & Healthy Lifestyle Corp Access Event

27/11/2017 - 13:10

SCOTTSDALE, Ariz., Nov. 27, 2017 (GLOBE NEWSWIRE) -- The Joint Corp. (NASDAQ: JYNT ), a national operator, manager and franchisor of chiropractic clinics, announced it will conduct one-on-one meetings at the 6 th Annual [...]

Intercept Pharmaceuticals Appoints Christian Weyer as Executive Vice President of Research & Development

27/11/2017 - 13:05

NEW YORK, Nov. 27, 2017 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT ), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non- [...]

Protalix BioTherapeutics Presents Positive Results from the Phase I/II Open-Label Extension Trial for PRX-102 at the New Horizons for Fabry Disease Conference

27/11/2017 - 13:00

Continued to Demonstrate Improvement across all Key Fabry Disease Parameters at 24 Months Low Incidence of Treatment Induced Anti-Drug Antibodies which Reversed Entirely Following 12 Months of Treatment without [...]

GW Pharmaceuticals to Report Q4 and Year-End Financial Results and Host Conference Call on 4 December, 2017

27/11/2017 - 13:00

LONDON, Nov. 27, 2017 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq: GWPH ) (“GW” or “the Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its [...]

Catalyst Pharmaceuticals Announces Positive Top-Line Results from Second Phase 3 Clinical Trial of Firdapse® in Patients with Lambert-Eaton Myasthenic Syndrome

27/11/2017 - 12:30

-- Treatment with Firdapse Achieved Statistical Significance for Co-Primary Endpoints and Secondary Endpoint -- -- Positive Results to Support Planned NDA Submission in the First Quarter of 2018 -- -- Conference Call [...]

ContraVir Pharmaceuticals to Make Three Presentations at HEP DART 2017

27/11/2017 - 12:00

EDISON, N.J., Nov. 27, 2017 (GLOBE NEWSWIRE) -- ContraVir Pharmaceuticals, Inc. (NASDAQ: CTRV ), a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, announced [...]

INSYS Therapeutics, Inc. to Participate in the 29th Annual Piper Jaffray Healthcare Conference

27/11/2017 - 12:00

PHOENIX, Nov. 27, 2017 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ: INSY ) (“INSYS” or “the company”) announced today that Saeed Motahari, president and chief executive officer, and Andrew Long, chief financial [...]

GENFIT: Contributing Significantly to the European LITMUS Initiative on NASH Biomarkers

27/11/2017 - 08:22

GENFIT: Contributing Significantly to the European LITMUS Initiative on NASH Biomarkers GENFIT significantly contributes to LITMUS (The "Liver Investigation: Testing Marker Utility in Steatohepatitis" consortium), by [...]

GENFIT : Contribution significative à l'initiative européenne LITMUS sur les biomarqueurs NASH

27/11/2017 - 08:22

GENFIT : Contribution significative à l'initiative européenne LITMUS sur les biomarqueurs NASH GENFIT contribue de manière significative au consortium LITMUS (« Liver Investigation: Testing Marker Utility in [...]

Novartis' Ultibro® Breezhaler® significantly improved COPD patients' lung function after direct switch from Seretide®

27/11/2017 - 07:16

New data showed switching moderate-to-severe, symptomatic COPD patients from Seretide ® * to Ultibro ® Breezhaler ® improved lung function and was well tolerated. The FLASH study is the first randomized controlled trial [...]

EnvoyAI launches with 35 algorithms contributed by 14 newly-contracted artificial intelligence development partners

26/11/2017 - 13:44

CAMBRIDGE, Mass., Nov. 26, 2017 (GLOBE NEWSWIRE) -- Artificial intelligence platform provider, EnvoyAI ( www.envoyai.com ) today announced the launch of the EnvoyAI Exchange, a platform described by AuntMinnie as the " [...]